US20110150853A1 - Mycotoxin-reducing composition - Google Patents
Mycotoxin-reducing composition Download PDFInfo
- Publication number
- US20110150853A1 US20110150853A1 US12/447,837 US44783707A US2011150853A1 US 20110150853 A1 US20110150853 A1 US 20110150853A1 US 44783707 A US44783707 A US 44783707A US 2011150853 A1 US2011150853 A1 US 2011150853A1
- Authority
- US
- United States
- Prior art keywords
- mycotoxin
- composition
- enzyme
- foodstuff
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 231100000678 Mycotoxin Toxicity 0.000 claims abstract description 81
- 239000002636 mycotoxin Substances 0.000 claims abstract description 81
- 102000004190 Enzymes Human genes 0.000 claims abstract description 74
- 108090000790 Enzymes Proteins 0.000 claims abstract description 74
- 239000011230 binding agent Substances 0.000 claims abstract description 56
- 244000005700 microbiome Species 0.000 claims abstract description 38
- 229940088598 enzyme Drugs 0.000 claims description 73
- 239000003053 toxin Substances 0.000 claims description 63
- 231100000765 toxin Toxicity 0.000 claims description 63
- 108700012359 toxins Proteins 0.000 claims description 63
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 31
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 23
- LINOMUASTDIRTM-QGRHZQQGSA-N deoxynivalenol Chemical compound C([C@@]12[C@@]3(C[C@@H](O)[C@H]1O[C@@H]1C=C(C([C@@H](O)[C@@]13CO)=O)C)C)O2 LINOMUASTDIRTM-QGRHZQQGSA-N 0.000 claims description 23
- LINOMUASTDIRTM-UHFFFAOYSA-N vomitoxin hydrate Natural products OCC12C(O)C(=O)C(C)=CC1OC1C(O)CC2(C)C11CO1 LINOMUASTDIRTM-UHFFFAOYSA-N 0.000 claims description 23
- 229930002954 deoxynivalenol Natural products 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 241000282414 Homo sapiens Species 0.000 claims description 18
- 102000004882 Lipase Human genes 0.000 claims description 16
- 108090001060 Lipase Proteins 0.000 claims description 16
- 239000003008 fumonisin Substances 0.000 claims description 15
- 239000004367 Lipase Substances 0.000 claims description 14
- 235000019421 lipase Nutrition 0.000 claims description 14
- 102000004316 Oxidoreductases Human genes 0.000 claims description 13
- 108090000854 Oxidoreductases Proteins 0.000 claims description 13
- 231100000419 toxicity Toxicity 0.000 claims description 13
- 230000001988 toxicity Effects 0.000 claims description 13
- MBMQEIFVQACCCH-QBODLPLBSA-N zearalenone Chemical compound O=C1O[C@@H](C)CCCC(=O)CCC\C=C\C2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-QBODLPLBSA-N 0.000 claims description 13
- MBMQEIFVQACCCH-UHFFFAOYSA-N trans-Zearalenon Natural products O=C1OC(C)CCCC(=O)CCCC=CC2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-UHFFFAOYSA-N 0.000 claims description 12
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 10
- 229910000278 bentonite Inorganic materials 0.000 claims description 9
- 239000000440 bentonite Substances 0.000 claims description 9
- -1 lactonohydrolase Proteins 0.000 claims description 7
- 108010017796 epoxidase Proteins 0.000 claims description 6
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 5
- 229930195730 Aflatoxin Natural products 0.000 claims description 5
- 108090000371 Esterases Proteins 0.000 claims description 5
- 229920002581 Glucomannan Polymers 0.000 claims description 5
- 108010023244 Lactoperoxidase Proteins 0.000 claims description 5
- 102000045576 Lactoperoxidases Human genes 0.000 claims description 5
- 108010059896 Manganese peroxidase Proteins 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 5
- 239000005409 aflatoxin Substances 0.000 claims description 5
- 229940046240 glucomannan Drugs 0.000 claims description 5
- 229940057428 lactoperoxidase Drugs 0.000 claims description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 claims description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 5
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229930183344 ochratoxin Natural products 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 claims description 3
- BGHDUTQZGWOQIA-VQSKNWBGSA-N Ergovaline Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)C(C)C)C)C2)=C3C2=CNC3=C1 BGHDUTQZGWOQIA-VQSKNWBGSA-N 0.000 claims description 3
- HGBZMCXKHKZYBF-UHFFFAOYSA-N Lolitrem B Natural products N1C2=CC=C3C(=O)C4C(C)(C)OC(C)(C)C4CC3=C2C(CC2CCC34O)=C1C2(C)C4(C)CCC1C23OC2C2OC(C=C(C)C)OC(C)(C)C2O1 HGBZMCXKHKZYBF-UHFFFAOYSA-N 0.000 claims description 3
- HGBZMCXKHKZYBF-WZGHVFPCSA-N Lolitrem B Chemical group N1C2=CC=C3C(=O)[C@H]4C(C)(C)OC(C)(C)[C@@H]4CC3=C2C(C[C@@H]2CC[C@@]34O)=C1[C@]2(C)[C@@]4(C)CC[C@H]1[C@]23O[C@@H]2[C@@H]2O[C@H](C=C(C)C)OC(C)(C)[C@H]2O1 HGBZMCXKHKZYBF-WZGHVFPCSA-N 0.000 claims description 3
- SPWSUFUPTSJWNG-JJUKSXGLSA-N Roquefortine C Chemical compound N1([C@H](C(N2)=O)C[C@@]3([C@H]1NC=1C3=CC=CC=1)C(C)(C=C)C)C(=O)\C2=C/C1=CNC=N1 SPWSUFUPTSJWNG-JJUKSXGLSA-N 0.000 claims description 3
- 229930188346 Sporidesmin Natural products 0.000 claims description 3
- BGHDUTQZGWOQIA-RKUMIMICSA-N ergovaline Natural products O=C(N[C@@]1(C)C(=O)N2[C@H](C(C)C)C(=O)N3[C@@H]([C@]2(O)O1)CCC3)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23 BGHDUTQZGWOQIA-RKUMIMICSA-N 0.000 claims description 3
- SPWSUFUPTSJWNG-UHFFFAOYSA-N roquefortine C Natural products C=1C=CC=C2C=1NC1C2(C(C)(C=C)C)CC(C(N2)=O)N1C(=O)C2=CC1=CN=CN1 SPWSUFUPTSJWNG-UHFFFAOYSA-N 0.000 claims description 3
- QTONANGUNATZOU-ICTVWZTPSA-N sporidesmin A Chemical compound S([C@](N(C1=O)C)(C)C(=O)N23)S[C@@]21[C@H](O)[C@@]1(O)[C@@H]3N(C)C2=C(OC)C(OC)=C(Cl)C=C21 QTONANGUNATZOU-ICTVWZTPSA-N 0.000 claims description 3
- QTONANGUNATZOU-UHFFFAOYSA-N sporidesmin-A Natural products N12C(=O)C(N(C3=O)C)(C)SSC23C(O)C2(O)C1N(C)C1=C(OC)C(OC)=C(Cl)C=C12 QTONANGUNATZOU-UHFFFAOYSA-N 0.000 claims description 3
- 230000024033 toxin binding Effects 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 description 24
- 238000006731 degradation reaction Methods 0.000 description 20
- 230000027455 binding Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 241000282887 Suidae Species 0.000 description 9
- 235000012216 bentonite Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229940092782 bentonite Drugs 0.000 description 8
- 238000001784 detoxification Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 235000013339 cereals Nutrition 0.000 description 7
- 244000144980 herd Species 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 244000144977 poultry Species 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009919 sequestration Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 108010059892 Cellulase Proteins 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940106157 cellulase Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 108010002430 hemicellulase Proteins 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000004927 clay Substances 0.000 description 3
- ONCZQWJXONKSMM-UHFFFAOYSA-N dialuminum;disodium;oxygen(2-);silicon(4+);hydrate Chemical compound O.[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Al+3].[Al+3].[Si+4].[Si+4].[Si+4].[Si+4] ONCZQWJXONKSMM-UHFFFAOYSA-N 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 229940059442 hemicellulase Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000013379 molasses Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910000280 sodium bentonite Inorganic materials 0.000 description 3
- 229940080314 sodium bentonite Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 108020005199 Dehydrogenases Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000209082 Lolium Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910000281 calcium bentonite Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000009144 enzymatic modification Effects 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940059904 light mineral oil Drugs 0.000 description 2
- 239000003863 metallic catalyst Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000222175 Diutina rugosa Species 0.000 description 1
- 241000228419 Epichloe coenophiala Species 0.000 description 1
- 241001265118 Epichloe festucae var. lolii Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000234643 Festuca arundinacea Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 108010054320 Lignin peroxidase Proteins 0.000 description 1
- 101710084378 Lipase 2 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 108010033272 Nitrilase Proteins 0.000 description 1
- GSPFUBNBRPVALJ-UHFFFAOYSA-N PR Toxin Natural products C1C2(C)C(C)C(OC(C)=O)C3OC3C2=CC(=O)C21OC2(C)C=O GSPFUBNBRPVALJ-UHFFFAOYSA-N 0.000 description 1
- GSPFUBNBRPVALJ-VIEAGMIOSA-N PR-toxin Chemical compound C1([C@@H]2O[C@@H]2[C@H](OC(C)=O)[C@@H]([C@]1(C1)C)C)=CC(=O)[C@]21O[C@]2(C)C=O GSPFUBNBRPVALJ-VIEAGMIOSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000305299 Pithomyces Species 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000004858 feed analysis Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/27—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/14—Pretreatment of feeding-stuffs with enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
- A23K10/37—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms from waste material
- A23K10/38—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms from waste material from distillers' or brewers' waste
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/28—Silicates, e.g. perlites, zeolites or bentonites
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/25—Removal of unwanted matter, e.g. deodorisation or detoxification using enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/27—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption
- A23L5/273—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption using adsorption or absorption agents, resins, synthetic polymers, or ion exchangers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/28—Removal of unwanted matter, e.g. deodorisation or detoxification using microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03003—D-Amino-acid oxidase (1.4.3.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01013—Manganese peroxidase (1.11.1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01025—1,4-Lactonase (3.1.1.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y303/00—Hydrolases acting on ether bonds (3.3)
- C12Y303/02—Ether hydrolases (3.3.2)
- C12Y303/02003—Epoxide hydrolase (3.3.2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Definitions
- This invention relates to reducing the mycotoxin content of a foodstuff.
- Mycotoxins are toxins produced by funghi that are known to affect adversely the nutrition and health of humans and animals.
- the production of mycotoxins is the result of the natural biological process of funghi and has occurred over thousands of years.
- mycotoxin production has been influenced by climate change and changes in agricultural practise.
- Mycotoxins are produced by a wide range of funghi including Aspergillus (Aflatoxin and Ochratoxin), Fusarium , (Zearalenone, Deoxynivalenol, Fumonisin) and Penicillium (PR toxin and Roquefortin). These toxins have a considerable pharmacological effect, even at very low concentrations (parts per billion), while toxicity may be further enhanced by metabolism in vivo, particularly by the liver. Detoxification of most toxins occurs in the liver, while in the gastro-intestinal tract (GIT), under certain conditions, detoxification may also be achieved by micro-organisms.
- Aflatoxins Aflatoxins
- trichothenes for example Deoxynivalenol
- Zearalenone group the Fumonisins
- endophyte toxins Aflatoxins, the trichothenes (for example Deoxynivalenol), the Zearalenone group, the Fumonisins and the endophyte toxins.
- Aflatoxins can cause growth reduction, suppressed immunity, reduced feed efficiency and increased mortality in cattle, among other symptoms. In pigs, reduced feed efficiency, increased mortality, and lower growth rates can be observed. In poultry, there are similar symptoms and a decreased ability to metabolize fat, protein and starch.
- Zearalenone in cattle and pigs mimics oestrogen and produces a considerable reduction in reproductive performance, reduced growth, reduced milk production and reduced feed efficiency. In poultry, increased mortality is observed.
- Deoxynivalenol an example of a trichothene, causes severe symptoms in cattle, pigs and poultry, including gastric effects such as vomiting, reduced growth rates, reduced egg production, scours and reduced feed efficiency.
- Fumonisin produces negative effects via a reduction in blood circulation and cardiac output, at least in part by agonising sphingosine receptors. In this way they reduce growth and cause pulmonary oedema in swine and poultry. This reduction of circulation affects all major organs including the liver and can exacerbate and enhance the effects of other toxins that may also be present.
- Ochratoxin can be carcinogenic in man and produces immuno-suppression in farm animals.
- Lolitrem B ( Acremonium lolii in Ryegrass) is an example of an endophyte toxin that produces a form of grass staggers often confused with hypomagnesaemia.
- Sporidesmin ( Pithomyces spp. in Ryegrass) is an endophyte that causes facial eczema and liver damage in sheep.
- Ergovaline ( Acremonium coenophialum ) is an endophyte toxin found in tall fescue, which reduces prolactin release and reduces blood flow.
- mycotoxin-binding agents such as bentonite clay
- binding and removal of mycotoxins are only partly successful. Some mycotoxins remain toxic even when attached to a binding agent, while some toxins do not bind efficiently at normal in vivo concentrations. Higher contamination levels are also an issue as the current recommended levels of binders may not be sufficient to remove all toxins present.
- An alternative technique is to add to foodstuffs enzymes, or microorganisms, that break down mycotoxins, to reduce toxicity.
- this is often not effective at reducing mycotoxin content sufficiently, which may be due to a dynamic equilibrium in the gasto-intestinal tract, which prevents excretion of the toxins.
- the present invention is based on the surprising realisation that a composition containing an enzyme, a mycotoxin-binding agent and a microorganism capable of taking up a mycotoxin is unexpectedly effective at reducing mycotoxin toxicity.
- a composition comprises an enzyme, a mycotoxin-binding agent and a microorganism capable of taking up a mycotoxin.
- a method of reducing the toxicity of a mycotoxin in a foodstuff comprises the step of contacting the foodstuff with a composition as defined above.
- a foodstuff comprises a composition as defined above.
- a composition as defined above is useful in therapy, in particular the treatment of a disease caused by a mycotoxin.
- a composition as defined above is used in the manufacture of a medicament for the treatment of a disease caused by a mycotoxin.
- FIG. 1 is a graph indicating the binding percentage of various mycotoxins and mycotoxin-binding agents
- FIG. 2 illustrates the effect of Saccharomyces cerevisiae uptake of DON, which is then modified by the yeast, followed by release and binding of the modified toxin to bentonite;
- FIG. 3 illustrates the effect of Saccharomyces cerevisiae uptake of Zearalenone
- FIG. 4 illustrates the reduction of fumonisin using Saccharomyces cerevisiae
- FIG. 5 shows the increase in milk production seen in a dairy herd, contaminated with Deoxynivalenol and Zearalenone, after application of a composition according to the invention.
- FIG. 6 shows the increase in milk production seen in a dairy herd, contaminated with Vomitoxin, after application of a composition according to the invention.
- the invention is based on the finding that combining an enzyme, a mycotoxin-binding agent and a microorganism that is capable of taking up a mycotoxin is surprisingly effective at reducing the toxicity of mycotoxins present in a foodstuff.
- the present inventor has realised that, when an enzyme alone is used, a dynamic equilibrium exists that prevents toxins from being defecated. Therefore, the sequestration by a microorganism and binding by a binding agent act as an aid to the ultimate degradation of the toxin by the enzymes and, optionally, microorganisms in the composition.
- an enzyme is to be given its usual meaning in the art, i.e. a biological catalyst.
- an enzyme is a protein.
- the enzyme is preferably at least partially purified, i.e. is provided as a cell extract, isolate or purified preparation.
- the enzyme is present in the composition in addition to any enzymes present in the microorganism, i.e. the enzymes, microorganism and mycotoxin-binding agent are present as three separate components of the composition.
- the purpose of the enzyme in the composition of the invention is to modify one or more mycotoxins, to reduce the toxicity of the toxin.
- the enzyme breaks down the toxin, partially or completely, thereby removing the toxicity of the toxin.
- the one or more enzymes of the composition preferably break down the toxin.
- the enzyme may further induce a modification of a toxin so that binding to the binding agent is increased, pending further degradation.
- the inventor believes that epoxidation and/or dehydrogenation of the toxin, in particular, improves binding.
- An increase in binding of the toxin to the binding agent may be detected by a toxin binding assay, as detailed in Example B, experiment 4.
- Other enzymes, that do not necessarily act directly upon a mycotoxin may be used to produce radicals that modify the toxin. This may be achieved with or without binding of the toxin to the enzyme.
- An example of a suitable enzyme of this type is lignin peroxidase.
- the enzyme may be replaced with a biomimetic catalyst (such as the haem prosthetic group), an organo-metallic catalyst or a metallic catalyst.
- Any enzyme, or combination of enzymes, with the ability to reduce the toxicity of a mycotoxin is within the scope of the invention.
- Preferred enzymes include an esterase, lipase, protease, oxidase, amino acid oxidase, lactonohydrolase, peroxidase, lactoperoxidase, manganese peroxidase, epoxidase, polysaccharase and dehydrogenase. Any combination of preferred enzymes can be used and the skilled person will realise that the specific combination of enzymes required may depend on the toxin or toxins to be treated.
- Particularly preferred enzymes include cellulases, epoxidases, dehydrogenases, hemicellulases (also known as xylanases) and lipases, preferably a triacylglycerol lipase (E.C. number 3.1.1.3), such as lipase AE 02 (obtainable from Candida Rugosa and commercially available from Mann Associates, Cambridge, UK) or “Lipase OF” (commercially available from Meito Sangyo, Japan).
- the combination preferably includes a lipase.
- a preferred combination of enzymes is the combination of a cellulase, a hemicellulase (xylanase) and a lipase.
- a preferred combination of enzymes suitable for use in the invention is shown in Table 2, below.
- the second component of the composition according to the invention is a mycotoxin-binding agent.
- One or more binding agents can be included. Preferably, 2, 3, 4 or more different binding agents are included.
- binding refers both to ionic or covalent chemical bonding and weaker physical adsorption involving van der waals interactions and/or hydrogen bonding.
- the binding agent has a charged surface. The charge may be positive or negative.
- Binding refers to the non-transient association of a mycotoxin to the binding agent.
- the binding has a minimum affinity between the mycotoxin and binding agent such that 10 mg of binding agent will bind 50% of a 200 ⁇ g/l (i.e. physiological) concentration of toxin.
- Binding may be determined using the method provided in Example B, experiment 4.
- Mycotoxin-binding agents are known in the art; examples of suitable binding agents are zeolites, montmorillonite, bentonite clays, diatomaceous earth, activated charcoals, fibrous plant materials such as wheat bran and alfalfa fibre, yeast cell wall extract and polysaccharides. Any agent that can bind a mycotoxin or a mycotoxin breakdown product is within the scope of the invention.
- Preferred mycotoxin-binding agents include a bentonite clay, preferably sodium bentonite or more preferably calcium bentonite, and a polysaccharide, preferably glucomannan, more preferably an esterified glucomannan.
- the glucomannan is preferably obtained as a yeast cell wall extract, as is recognised in the art.
- Glucomannan-containing mycotoxin adsorbents are commercially available, for example Mycosorb®, obtainable from Alltech UK, Stamford, UK.
- the binding agent has at least one ionic, i.e. charged, surface, which will allow (strong) ionic bonding between the toxin and binding agent to occur.
- the charge may be positive or negative.
- ionic binding agents are bentonites such as sodium bentonite and calcium bentonite.
- the third component of the composition according to the invention is a microorganism.
- the term “microorganism” refers to bacteria and yeasts. The skilled person will recognise that the microorganism is preferably not harmful to the health of the human or animal which will ingest the foodstuff to which the composition will be applied, i.e. the microorganism is preferably non-pathogenic.
- the purpose of the microorganism is to uptake mycotoxins. Any microorganism that can uptake mycotoxins can be used according to the invention. Once taken up, the microorganism sequesters the toxin, which cannot then be taken up by the host animal. The microorganism's endogenous enzymes may then breakdown the toxins, although this is not an absolute requirement.
- the microorganism is a yeast, more preferably a saccharomyces , most preferably Saccharomyces cerevisiae.
- the microorganism has the function of physically taking up the toxin to sequester it within the bacterial or yeast cell.
- the toxin is modified in the cell and analogues are released, which are then able to bind to the binders where further enzyme degradation can take place. Therefore, in a preferred embodiment, the microorganism additionally performs a second function, that of expressing one or more enzymes capable of breaking down a mycotoxin.
- One or more different microorganisms can be included in the composition of the invention.
- at least two microorganisms are included; the first microorganism is primarily responsible for mycotoxin uptake and the second is primarily responsible for mycotoxin degrading enzyme expression.
- the composition must still contain the enzyme component as a separate component of the composition.
- Example Composition according to the Invention. Approx Name Source/Company Specification kg % wt FerMos JACKLYN IND FerMos, 25 kg Bags 7.445 35% Mannan oligosaccharide (Binding Agent) Terra-Green OIL DRI Terra-Green, 24/48 6.68742 30% 24/48 LVM LVM, 50 lb bags (Binding Agent) Sodium Eastern Mineral Sodium Bentonite 2.06116 10% bentonite Granular (Binding Agent) Diabond Eastern Mineral 200 Bags of Diabond 2.06116 10% Granular granular, 50 lb bags (Binding Agent) Dried molasses Bartlett Milling Dried molasses, 50 lb 1.03058 5% bags.
- additional components can be included in a composition of the invention, if necessary.
- suitable additional components are food supplements such as vitamins and minerals, mineral oil, a flow agent such as a fine, precipitated calcium silicate powder (e.g. hubersorb), and a sugar source such as dried molasses.
- An example of a formulation according to the invention is provided in Table 1.
- the three essential components are preferably prepared as a mixture, optionally with a flow agent (as in Table 2), and subsequently combined with the additional components when needed for application to a foodstuff.
- a flow agent as in Table 2
- any amount of each of the three essential components of the composition can be used that achieves the desired result of reducing mycotoxin levels.
- Preferably, between 0.1 kg and 50 kg of the composition is applied to each tonne of feed, more preferably between 0.2 kg and 10 kg per tonne, e.g. 0.5, 1, 1.2, 1.5, 2.5, 5, 7.5 kg or more per tonne. Suitable levels will be apparent to the skilled person.
- the composition is applied to the feed such that the microorganism is present at approximately 1 ⁇ 10 9 cells per tonne of feed or greater. More preferably, the microorganism is present at 2 ⁇ 10 9 , 3 ⁇ 10 9 , 4 ⁇ 10 9 , or 5 ⁇ 10 9 cells per tonne of feed or greater. Yet more preferably, 1 ⁇ 10 10 cells per tonne of feed is applied, more preferably 1 ⁇ 10 11 cells per tonne of feed or greater is applied, for example greater than 2 ⁇ 10 11 cells per tonne of feed, more preferably greater than 1 ⁇ 10 12 , 2 ⁇ 10 12 cells per tonne of feed or more.
- compositions that is required per tonne of feed will depend on the feed to be treated, the toxins present and the intended recipient of the feed.
- an animal that consumes a small amount of feed per day will generally require a higher concentration of microorganism applied to the feed than an animal that consumes a large amount of feed per day.
- a suitable amount is 2.2 ⁇ 10 11 cells per tonne of feed, while for swine and poultry a preferred amount is 1.1 ⁇ 10 12 cells per tonne of feed.
- the microorganism is present at any suitable level that allows detoxification to occur when applied to a foodstuff.
- the microorganism is present at approximately 1 ⁇ 10 9 cells or greater per kilogram of the composition, more preferably 1 ⁇ 10 10 cells per kilogram of composition, or greater, for example 1 ⁇ 10 11 or 1 ⁇ 10 12 cells per kilogram, or greater.
- the skilled person will appreciate that the amount of microorganism in the composition will affect the amount of composition required to achieve the desired effect, in particular the cells per tonne of feed recited above.
- yeast is included at approx 5% (by weight).
- 1 Kg of the composition defined by Table 1 contains approximately 5 ⁇ 10 11 yeast cells.
- the one or more enzyme is present in the composition at an effective level. Less than 5% by weight of enzyme is preferred, more preferably less than 1%, more preferably between 0.01% and 0.5% by weight, yet more preferably between 0.15% and 0.25% by weight.
- the composition of Table 1 contains an enzyme mixture totalling 0.16% by weight, including the flow agent.
- the binder is present in the largest proportion, at an effective level.
- at least 50% by weight of the composition should be binding agent, more preferably 60 to 90%.
- the composition of Table 1 contains a mixture of binding agents totalling approx 85%.
- a suitable range for each of the essential ingredients in the composition of the invention is: microorganism—0.1% to 10% by weight, preferably 2% to 8%, i.e. 5%; enzyme—less than 5% by weight of enzyme is preferred, more preferably less than 1%, more preferably between 0.01% and 0.5% by weight, yet more preferably between 0.15% and 0.25% by weight; binder—preferably at least 50% by weight of the composition is binding agent, more preferably 60 to 90%.
- the balance (if any) can be made up with the additional agents recited above, if required.
- composition of the invention can be in any suitable formulation, for example a solid such as a powder or granulate, a gel or a liquid.
- a solid such as a powder or granulate, a gel or a liquid.
- the formulation is a solid, more preferably a powder.
- the composition of the invention is effective at reducing mycotoxin levels.
- the composition is used to reduce mycotoxins in a foodstuff.
- foodstuff is to be given its usual meaning in the art, referring to any material that is eaten by a human or animal for nutrition.
- Foodstuffs comprise carbohydrates, fats and/or proteins among other components.
- the foodstuff can be of animal or vegetable origin. Human food and animal feeds are within the scope of the term.
- the foodstuff is an animal feed of plant origin, commonly known as fodder, more preferably a cereal foodstuff.
- the term “foodstuff” includes materials that must be processed before safe consumption by a human or animal.
- distiller's grains are a cereal by-product of the distillation process. Distiller's grains are known in the art. Briefly, they are produced in distilleries by drying mash and are used commonly as a fodder for livestock, especially ruminants. Detoxifying distiller's grains, by reduction of mycotoxin content, is therefore within the scope of the invention.
- the composition can be added to the foodstuff any way that is effective at reducing the mycotoxin content. Contact between the composition and foodstuff is required.
- the preferred method is to treat the foodstuff before ingestion to remove, preferably completely, the toxicity. This is “detoxification” of the foodstuff before consumption.
- An alternative method is to treat the feed immediately before ingestion, or simultaneous with ingestion, and to rely on the invention to complete the detoxification during digestion. This post-ingestion detoxification is particularly suitable for use in animals, preferably ruminants such as cattle and sheep.
- a method of reducing the toxicity of a mycotoxin or mycotoxins in a foodstuff comprises the step of contacting the foodstuff with a composition as defined herein.
- the mycotoxin can be any mycotoxin.
- Preferred mycotoxins include Zearalenone, a tricothene such as Deoxynivalenol, Aflatoxin, Fumonisin, Roquefortin, ochratoxin or an endophyte toxin, such as sporidesmin, ergovaline or Lolitrem B.
- a foodstuff of any human or non-human animal, preferably non-human mammal, can be detoxified according to the invention.
- the foodstuff is for a farm animal such as cattle, horses, pigs or poultry.
- detoxification is thought to be achieved in a number of ways, acting in synergy.
- the enzyme component breaks down toxins and/or improves the toxin binding to the mycotoxin-binding agent.
- the binding agent prevents the mycotoxins from being absorbed by the animal and allows their excretion.
- the microorganism uptakes and sequesters the toxins and may also break down the toxins. Any toxin that is released by the microorganism is thought to bind more strongly to the binding agent, where further degradation (by the enzymes) may occur. Therefore, the actions of the microorganism and/or enzyme are thought to potentiate the binding of the toxin to the binding agent.
- the toxin may therefore be removed from the foodstuff by enzyme breakdown, by binding to the binding agent and/or sequestration in the micro-organism, thus removing it from the foodstuff; if detoxification occurs in an animal, the removal is ultimately from the gastrointestinal tract in faecal material.
- sequestrations have the further effects of preventing absorption into the animal and facilitating the action of the enzymes of the invention in the gastrointestinal tract.
- compositions of the invention can therefore be used in therapy, to treat a disease caused by a mycotoxin.
- the modification of various toxins by enzymes was examined by screening the activity of a number of a selection of enzymes against various toxins.
- the change in the toxin was measured by a monoclonal antibody in an Elisa test. Since the monoclonal antibody retains, in many cases, the ability to cross react with the fragments produced by the enzyme catalysis, this provides a definitive screening tool but not a quantitative measure of the enzymes activity.
- Suitable enzymes which may be used as part of the invention are shown in Table 3 and examples of their action are shown in Tables 4-6.
- Lipase AE 02 Mann Associates, Cambridge, UK was incubated with Fumonisin 200 ⁇ g/litre and measured after 1 hour at 37° C. The remaining fumonisin was measured by ELISA assay. Boiled enzyme controls were also used in each case. It can be seen that there was a considerable reduction in the Fumonisin reacting with the antibody indicating degradation of the toxin.
- Fumonisin was further examined by incubating it as in Table 3, but with an aminoxidase to remove the amine groups.
- the lipase 2 again achieved degradation while the oxidase also degraded the toxin.
- Enzyme degradation of Zearalenone was examined using a variety of preparations. Of these preparations, some achieved degradation but the composition according to the invention (as defined in Table 1) produced a synergistic effect. Repeats of the experiment followed by analysis by HPLC showed that the formulation was capable of reducing the toxin levels to zero.
- Toxin at physiological levels of approx. 200 ⁇ g/L was mixed with a constant quantity (50 mg) of binder, agitated for 30 min, centrifuged and the toxin remaining in solution measured using a RIDASCREEN® FAST mycotoxin test kit (available from R-Biopharm GmbH, Darmstadt, Germany). The results are determined by reference to a standard binding curve for the toxin and binder.
- FIG. 1 shows the binding percentage at a typical (physiological) rumen concentration.
- the binding abilities of various components are demonstrated at a physiological concentration of toxin. It can be seen from the variability in the results that a mixture of binders is preferable to a single entity.
- FIGS. 2 , 3 , and 4 illustrate the effects of the microorganism and its endogenous microbial enzymes on the mycotoxins DON, Zearalenone and Fumonisin.
- the yeast take up the toxin, rapidly reducing the toxicity of the culture.
- the toxin is then metabolised and released, in an altered form, where it is able to bind the binding agent, for subsequent degradation.
- Yeast Saccharomyces Cerevisiae NYCC R404 rapidly take up DON from solution, preventing uptake into the animal.
- the yeast metabolise the DON and release break-down products (metabolites) which are able to bind to two different bentonite binders. Further degradation can then occur on the binders. See FIG. 2 .
- Yeast Saccharomyces Cerevisiae NYCC R404
- FIG. 5 shows that as the desired formulation (as defined in Table 1) was added, at a rate of 0.5 kilos/1000 kilos of feed for 2 days, and 0.25 kilos 1000 kilos of feed thereafter, milk production increased. Milk production is shown in lbs.
- Boars also benefited. Exposed to DON, their semen volume and sperm concentration decreased by 50% within 7 days. On treatment they returned to normal also in approximately 7 days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
Abstract
A composition comprising an enzyme, a mycotoxin-binding agent and a microorganism capable of taking up a mycotoxin.
Description
- This invention relates to reducing the mycotoxin content of a foodstuff.
- Mycotoxins are toxins produced by funghi that are known to affect adversely the nutrition and health of humans and animals. The production of mycotoxins is the result of the natural biological process of funghi and has occurred over thousands of years. However, mycotoxin production has been influenced by climate change and changes in agricultural practise.
- Mycotoxins are produced by a wide range of funghi including Aspergillus (Aflatoxin and Ochratoxin), Fusarium, (Zearalenone, Deoxynivalenol, Fumonisin) and Penicillium (PR toxin and Roquefortin). These toxins have a considerable pharmacological effect, even at very low concentrations (parts per billion), while toxicity may be further enhanced by metabolism in vivo, particularly by the liver. Detoxification of most toxins occurs in the liver, while in the gastro-intestinal tract (GIT), under certain conditions, detoxification may also be achieved by micro-organisms.
- A large number of mycotoxins have been identified. Currently, there are five main groups of particular agricultural interest: the Aflatoxins, the trichothenes (for example Deoxynivalenol), the Zearalenone group, the Fumonisins and the endophyte toxins.
- Aflatoxins can cause growth reduction, suppressed immunity, reduced feed efficiency and increased mortality in cattle, among other symptoms. In pigs, reduced feed efficiency, increased mortality, and lower growth rates can be observed. In poultry, there are similar symptoms and a decreased ability to metabolize fat, protein and starch.
- Zearalenone in cattle and pigs mimics oestrogen and produces a considerable reduction in reproductive performance, reduced growth, reduced milk production and reduced feed efficiency. In poultry, increased mortality is observed.
- Deoxynivalenol (DON), an example of a trichothene, causes severe symptoms in cattle, pigs and poultry, including gastric effects such as vomiting, reduced growth rates, reduced egg production, scours and reduced feed efficiency.
- Fumonisin produces negative effects via a reduction in blood circulation and cardiac output, at least in part by agonising sphingosine receptors. In this way they reduce growth and cause pulmonary oedema in swine and poultry. This reduction of circulation affects all major organs including the liver and can exacerbate and enhance the effects of other toxins that may also be present.
- Ochratoxin can be carcinogenic in man and produces immuno-suppression in farm animals.
- Lolitrem B (Acremonium lolii in Ryegrass) is an example of an endophyte toxin that produces a form of grass staggers often confused with hypomagnesaemia.
- Sporidesmin (Pithomyces spp. in Ryegrass) is an endophyte that causes facial eczema and liver damage in sheep.
- Ergovaline (Acremonium coenophialum) is an endophyte toxin found in tall fescue, which reduces prolactin release and reduces blood flow.
- It is in the interests of the health of both humans and animals that mycotoxins are reduced, or preferably removed altogether, from the food chain.
- Current techniques used to reduce mycotoxin content in a foodstuff involve the use of mycotoxin-binding agents, such as bentonite clay, to which the toxins bind and can therefore be removed with the clay. However, binding and removal of mycotoxins are only partly successful. Some mycotoxins remain toxic even when attached to a binding agent, while some toxins do not bind efficiently at normal in vivo concentrations. Higher contamination levels are also an issue as the current recommended levels of binders may not be sufficient to remove all toxins present.
- An alternative technique is to add to foodstuffs enzymes, or microorganisms, that break down mycotoxins, to reduce toxicity. However, this is often not effective at reducing mycotoxin content sufficiently, which may be due to a dynamic equilibrium in the gasto-intestinal tract, which prevents excretion of the toxins.
- An effective technique for reducing mycotoxin toxicity is therefore still required.
- The present invention is based on the surprising realisation that a composition containing an enzyme, a mycotoxin-binding agent and a microorganism capable of taking up a mycotoxin is unexpectedly effective at reducing mycotoxin toxicity.
- According to a first aspect of the invention, a composition comprises an enzyme, a mycotoxin-binding agent and a microorganism capable of taking up a mycotoxin.
- According to a second aspect of the invention, a method of reducing the toxicity of a mycotoxin in a foodstuff comprises the step of contacting the foodstuff with a composition as defined above.
- According to a third aspect of the invention, a foodstuff comprises a composition as defined above.
- According to a fourth aspect of the invention, a composition as defined above is useful in therapy, in particular the treatment of a disease caused by a mycotoxin.
- According to a fifth aspect of the invention, a composition as defined above is used in the manufacture of a medicament for the treatment of a disease caused by a mycotoxin.
- The invention is described with reference to the following figures, wherein:
-
FIG. 1 is a graph indicating the binding percentage of various mycotoxins and mycotoxin-binding agents; -
FIG. 2 illustrates the effect of Saccharomyces cerevisiae uptake of DON, which is then modified by the yeast, followed by release and binding of the modified toxin to bentonite; -
FIG. 3 illustrates the effect of Saccharomyces cerevisiae uptake of Zearalenone; -
FIG. 4 illustrates the reduction of fumonisin using Saccharomyces cerevisiae; -
FIG. 5 shows the increase in milk production seen in a dairy herd, contaminated with Deoxynivalenol and Zearalenone, after application of a composition according to the invention; and -
FIG. 6 shows the increase in milk production seen in a dairy herd, contaminated with Vomitoxin, after application of a composition according to the invention. - The invention is based on the finding that combining an enzyme, a mycotoxin-binding agent and a microorganism that is capable of taking up a mycotoxin is surprisingly effective at reducing the toxicity of mycotoxins present in a foodstuff.
- The present inventor has realised that, when an enzyme alone is used, a dynamic equilibrium exists that prevents toxins from being defecated. Therefore, the sequestration by a microorganism and binding by a binding agent act as an aid to the ultimate degradation of the toxin by the enzymes and, optionally, microorganisms in the composition.
- As used herein, the term “enzyme” is to be given its usual meaning in the art, i.e. a biological catalyst. For the avoidance of doubt, an enzyme is a protein. The enzyme is preferably at least partially purified, i.e. is provided as a cell extract, isolate or purified preparation. The enzyme is present in the composition in addition to any enzymes present in the microorganism, i.e. the enzymes, microorganism and mycotoxin-binding agent are present as three separate components of the composition. The purpose of the enzyme in the composition of the invention is to modify one or more mycotoxins, to reduce the toxicity of the toxin. Preferably, the enzyme breaks down the toxin, partially or completely, thereby removing the toxicity of the toxin.
- Therefore, the one or more enzymes of the composition preferably break down the toxin. The enzyme may further induce a modification of a toxin so that binding to the binding agent is increased, pending further degradation. Without wishing to be bound by theory, the inventor believes that epoxidation and/or dehydrogenation of the toxin, in particular, improves binding. An increase in binding of the toxin to the binding agent may be detected by a toxin binding assay, as detailed in Example B,
experiment 4. Other enzymes, that do not necessarily act directly upon a mycotoxin, may be used to produce radicals that modify the toxin. This may be achieved with or without binding of the toxin to the enzyme. An example of a suitable enzyme of this type is lignin peroxidase. In this embodiment, where radicals are used, the enzyme may be replaced with a biomimetic catalyst (such as the haem prosthetic group), an organo-metallic catalyst or a metallic catalyst. - Any enzyme, or combination of enzymes, with the ability to reduce the toxicity of a mycotoxin is within the scope of the invention. Preferred enzymes include an esterase, lipase, protease, oxidase, amino acid oxidase, lactonohydrolase, peroxidase, lactoperoxidase, manganese peroxidase, epoxidase, polysaccharase and dehydrogenase. Any combination of preferred enzymes can be used and the skilled person will realise that the specific combination of enzymes required may depend on the toxin or toxins to be treated. Particularly preferred enzymes include cellulases, epoxidases, dehydrogenases, hemicellulases (also known as xylanases) and lipases, preferably a triacylglycerol lipase (E.C. number 3.1.1.3), such as lipase AE 02 (obtainable from Candida Rugosa and commercially available from Mann Associates, Cambridge, UK) or “Lipase OF” (commercially available from Meito Sangyo, Japan). The combination preferably includes a lipase. A preferred combination of enzymes is the combination of a cellulase, a hemicellulase (xylanase) and a lipase. A preferred combination of enzymes suitable for use in the invention is shown in Table 2, below.
- The second component of the composition according to the invention is a mycotoxin-binding agent. One or more binding agents can be included. Preferably, 2, 3, 4 or more different binding agents are included. The term “binding” refers both to ionic or covalent chemical bonding and weaker physical adsorption involving van der waals interactions and/or hydrogen bonding. In a preferred embodiment, the binding agent has a charged surface. The charge may be positive or negative. Binding refers to the non-transient association of a mycotoxin to the binding agent. In a preferred embodiment, the binding has a minimum affinity between the mycotoxin and binding agent such that 10 mg of binding agent will bind 50% of a 200 μg/l (i.e. physiological) concentration of toxin. Binding may be determined using the method provided in Example B,
experiment 4. Mycotoxin-binding agents are known in the art; examples of suitable binding agents are zeolites, montmorillonite, bentonite clays, diatomaceous earth, activated charcoals, fibrous plant materials such as wheat bran and alfalfa fibre, yeast cell wall extract and polysaccharides. Any agent that can bind a mycotoxin or a mycotoxin breakdown product is within the scope of the invention. Preferred mycotoxin-binding agents include a bentonite clay, preferably sodium bentonite or more preferably calcium bentonite, and a polysaccharide, preferably glucomannan, more preferably an esterified glucomannan. The glucomannan is preferably obtained as a yeast cell wall extract, as is recognised in the art. Glucomannan-containing mycotoxin adsorbents are commercially available, for example Mycosorb®, obtainable from Alltech UK, Stamford, UK. - Preferably, the binding agent has at least one ionic, i.e. charged, surface, which will allow (strong) ionic bonding between the toxin and binding agent to occur. The charge may be positive or negative. Examples of ionic binding agents are bentonites such as sodium bentonite and calcium bentonite.
- The third component of the composition according to the invention is a microorganism. As used herein, the term “microorganism” refers to bacteria and yeasts. The skilled person will recognise that the microorganism is preferably not harmful to the health of the human or animal which will ingest the foodstuff to which the composition will be applied, i.e. the microorganism is preferably non-pathogenic. The purpose of the microorganism is to uptake mycotoxins. Any microorganism that can uptake mycotoxins can be used according to the invention. Once taken up, the microorganism sequesters the toxin, which cannot then be taken up by the host animal. The microorganism's endogenous enzymes may then breakdown the toxins, although this is not an absolute requirement. Preferably, the microorganism is a yeast, more preferably a saccharomyces, most preferably Saccharomyces cerevisiae.
- The microorganism has the function of physically taking up the toxin to sequester it within the bacterial or yeast cell. In the case of one toxin at least (DON), the toxin is modified in the cell and analogues are released, which are then able to bind to the binders where further enzyme degradation can take place. Therefore, in a preferred embodiment, the microorganism additionally performs a second function, that of expressing one or more enzymes capable of breaking down a mycotoxin.
- One or more different microorganisms can be included in the composition of the invention. In one embodiment, at least two microorganisms are included; the first microorganism is primarily responsible for mycotoxin uptake and the second is primarily responsible for mycotoxin degrading enzyme expression. For the avoidance of doubt, in the embodiments where a microorganism expresses one or more enzymes capable of breaking down a mycotoxin, the composition must still contain the enzyme component as a separate component of the composition.
-
TABLE 1 Example Composition according to the Invention. Approx Name Source/Company Specification kg % wt FerMos JACKLYN IND FerMos, 25 kg Bags 7.445 35% Mannan oligosaccharide (Binding Agent) Terra-Green OIL DRI Terra-Green, 24/48 6.68742 30% 24/48 LVM LVM, 50 lb bags (Binding Agent) Sodium Eastern Mineral Sodium Bentonite 2.06116 10% bentonite Granular (Binding Agent) Diabond Eastern Mineral 200 Bags of Diabond 2.06116 10% Granular granular, 50 lb bags (Binding Agent) Dried molasses Bartlett Milling Dried molasses, 50 lb 1.03058 5% bags. S. cerevisiae JACKLYN IND Bulk Yeast 10 B/g, 20 kg 1 5% Yeast box Vitamin A, A-30 RC BWATER Vitamin A, A-30, 50 lb 0.51529 2% bag Vitamin E, E-20 RC BWATER Vitamin E, E-20, 50 lb 0.51529 2% bag Enzyme Premix Micron Mycotex SW enzymes 0.03405 <1% IV (See Table (0.16%) 2) Light mineral oil AKEY Light mineral oil, 387 lb 0.22809 1% drum TOTAL 21.53204 100.00% -
TABLE 2 Enzyme Formulation suitable for use in the Composition of the Invention Name Source Specification kg % wt Cellulase 300 BIOCAT Cellulase 300 0.49000 32.67% TR TR, 75,000/g, Hemicellulase BIOCAT Hemicellulase 0.49000 32.67% 1500 1500 Lipase OF Meito 400,000 U/g 0.49000 32.67% Sangyo Flow Agent DUNLEARY Hubersorb 600, 0.03000 2.00% 30 lb bag TOTAL 1.50000 100.00% - In addition to these essential components, additional components can be included in a composition of the invention, if necessary. Examples of suitable additional components are food supplements such as vitamins and minerals, mineral oil, a flow agent such as a fine, precipitated calcium silicate powder (e.g. hubersorb), and a sugar source such as dried molasses. An example of a formulation according to the invention is provided in Table 1.
- The three essential components are preferably prepared as a mixture, optionally with a flow agent (as in Table 2), and subsequently combined with the additional components when needed for application to a foodstuff.
- Any amount of each of the three essential components of the composition can be used that achieves the desired result of reducing mycotoxin levels. Preferably, between 0.1 kg and 50 kg of the composition is applied to each tonne of feed, more preferably between 0.2 kg and 10 kg per tonne, e.g. 0.5, 1, 1.2, 1.5, 2.5, 5, 7.5 kg or more per tonne. Suitable levels will be apparent to the skilled person.
- In a preferred embodiment, the composition is applied to the feed such that the microorganism is present at approximately 1×109 cells per tonne of feed or greater. More preferably, the microorganism is present at 2×109, 3×109, 4×109, or 5×109 cells per tonne of feed or greater. Yet more preferably, 1×1010 cells per tonne of feed is applied, more preferably 1×1011 cells per tonne of feed or greater is applied, for example greater than 2×1011 cells per tonne of feed, more preferably greater than 1×1012, 2×1012 cells per tonne of feed or more. The skilled person will realise that the precise amount of composition that is required per tonne of feed will depend on the feed to be treated, the toxins present and the intended recipient of the feed. For example, an animal that consumes a small amount of feed per day will generally require a higher concentration of microorganism applied to the feed than an animal that consumes a large amount of feed per day. For cattle, an example of a suitable amount is 2.2×1011 cells per tonne of feed, while for swine and poultry a preferred amount is 1.1×1012 cells per tonne of feed.
- In the composition, the microorganism is present at any suitable level that allows detoxification to occur when applied to a foodstuff. Preferably, the microorganism is present at approximately 1×109 cells or greater per kilogram of the composition, more preferably 1×1010 cells per kilogram of composition, or greater, for example 1×1011 or 1×1012 cells per kilogram, or greater. The skilled person will appreciate that the amount of microorganism in the composition will affect the amount of composition required to achieve the desired effect, in particular the cells per tonne of feed recited above. In the example composition of Table 1, yeast is included at approx 5% (by weight). 1 Kg of the composition defined by Table 1 contains approximately 5×1011 yeast cells. Therefore, applying 0.5 Kg of this composition to a tonne of feed will provide approximately 2.5×1011 cells per tonne of feed, while applying 2.5 Kg of this composition to a tonne of feed will provide approximately 1.25×1012 cells per tonne of feed.
- The one or more enzyme is present in the composition at an effective level. Less than 5% by weight of enzyme is preferred, more preferably less than 1%, more preferably between 0.01% and 0.5% by weight, yet more preferably between 0.15% and 0.25% by weight. The composition of Table 1 contains an enzyme mixture totalling 0.16% by weight, including the flow agent.
- The binder is present in the largest proportion, at an effective level. Preferably, at least 50% by weight of the composition should be binding agent, more preferably 60 to 90%. The composition of Table 1 contains a mixture of binding agents totalling approx 85%.
- For the avoidance of doubt, a suitable range for each of the essential ingredients in the composition of the invention is: microorganism—0.1% to 10% by weight, preferably 2% to 8%, i.e. 5%; enzyme—less than 5% by weight of enzyme is preferred, more preferably less than 1%, more preferably between 0.01% and 0.5% by weight, yet more preferably between 0.15% and 0.25% by weight; binder—preferably at least 50% by weight of the composition is binding agent, more preferably 60 to 90%. The balance (if any) can be made up with the additional agents recited above, if required.
- The composition of the invention can be in any suitable formulation, for example a solid such as a powder or granulate, a gel or a liquid. Preferably, the formulation is a solid, more preferably a powder.
- The composition of the invention is effective at reducing mycotoxin levels. Preferably, the composition is used to reduce mycotoxins in a foodstuff. As used herein, the term “foodstuff” is to be given its usual meaning in the art, referring to any material that is eaten by a human or animal for nutrition. Foodstuffs comprise carbohydrates, fats and/or proteins among other components. The foodstuff can be of animal or vegetable origin. Human food and animal feeds are within the scope of the term. In a preferred embodiment, the foodstuff is an animal feed of plant origin, commonly known as fodder, more preferably a cereal foodstuff. The term “foodstuff” includes materials that must be processed before safe consumption by a human or animal. A preferred example of such a material are “distiller's grains”. These grains, also known as “distiller's dried grains”, are a cereal by-product of the distillation process. Distiller's grains are known in the art. Briefly, they are produced in distilleries by drying mash and are used commonly as a fodder for livestock, especially ruminants. Detoxifying distiller's grains, by reduction of mycotoxin content, is therefore within the scope of the invention.
- The composition can be added to the foodstuff any way that is effective at reducing the mycotoxin content. Contact between the composition and foodstuff is required. The preferred method is to treat the foodstuff before ingestion to remove, preferably completely, the toxicity. This is “detoxification” of the foodstuff before consumption. An alternative method is to treat the feed immediately before ingestion, or simultaneous with ingestion, and to rely on the invention to complete the detoxification during digestion. This post-ingestion detoxification is particularly suitable for use in animals, preferably ruminants such as cattle and sheep.
- A method of reducing the toxicity of a mycotoxin or mycotoxins in a foodstuff comprises the step of contacting the foodstuff with a composition as defined herein. The mycotoxin can be any mycotoxin. Preferred mycotoxins include Zearalenone, a tricothene such as Deoxynivalenol, Aflatoxin, Fumonisin, Roquefortin, ochratoxin or an endophyte toxin, such as sporidesmin, ergovaline or Lolitrem B.
- A foodstuff of any human or non-human animal, preferably non-human mammal, can be detoxified according to the invention. Preferably, the foodstuff is for a farm animal such as cattle, horses, pigs or poultry.
- Without wishing to be bound by theory, detoxification is thought to be achieved in a number of ways, acting in synergy. The enzyme component breaks down toxins and/or improves the toxin binding to the mycotoxin-binding agent. The binding agent prevents the mycotoxins from being absorbed by the animal and allows their excretion. The microorganism uptakes and sequesters the toxins and may also break down the toxins. Any toxin that is released by the microorganism is thought to bind more strongly to the binding agent, where further degradation (by the enzymes) may occur. Therefore, the actions of the microorganism and/or enzyme are thought to potentiate the binding of the toxin to the binding agent. These three components therefore work in an advantageous complex synergy that could not be predicted.
- The toxin may therefore be removed from the foodstuff by enzyme breakdown, by binding to the binding agent and/or sequestration in the micro-organism, thus removing it from the foodstuff; if detoxification occurs in an animal, the removal is ultimately from the gastrointestinal tract in faecal material. These sequestrations have the further effects of preventing absorption into the animal and facilitating the action of the enzymes of the invention in the gastrointestinal tract.
- The skilled person will realise that the health of animals and humans can be adversely affected by the presence of a mycotoxin in a foodstuff. The compositions of the invention can therefore be used in therapy, to treat a disease caused by a mycotoxin.
- The invention is further described with reference to the following non-limiting examples.
- The modification of various toxins by enzymes was examined by screening the activity of a number of a selection of enzymes against various toxins. The change in the toxin was measured by a monoclonal antibody in an Elisa test. Since the monoclonal antibody retains, in many cases, the ability to cross react with the fragments produced by the enzyme catalysis, this provides a definitive screening tool but not a quantitative measure of the enzymes activity.
- Suitable enzymes which may be used as part of the invention are shown in Table 3 and examples of their action are shown in Tables 4-6.
-
TABLE 3 Examples of the Enzymes suitable for use in the Composition of the Invention. ENZYME EC NUMBER ACTION Esterase 3.1.1.x Ester hydrolysis Lipase 3.1.1.3 Ester hydrolysis Protease 3.4.x.x Hydrolysis of peptides Oxidase 1.4.3 Oxidations Aminoacid oxidase 1.4.3.2 & 3 Oxidation of amino acid NH2 Lacotonohydrolase 3.1.1.25 Hydrolysis of lactones Peroxidase 1.11.1.7 Peroxidation reactions Lactoperoxidase 1.11.1.7 Peroxidation reactions Manganese peroxidase 1.11.1.13 Production of Mn+++ Epoxidase 3.3.2.3 Hydrolysis of peroxides Polysaccharase 3.2.1 Hydrolysis of sugar cross links Dehydrogenases 1.1 Oxidation by removal of hydrogen - Lipase AE 02 (Mann Associates, Cambridge, UK) was incubated with
Fumonisin 200 μg/litre and measured after 1 hour at 37° C. The remaining fumonisin was measured by ELISA assay. Boiled enzyme controls were also used in each case. It can be seen that there was a considerable reduction in the Fumonisin reacting with the antibody indicating degradation of the toxin. -
TABLE 4 pH 6.4 pH4.5 No Buffer Std Norm 0.06 0.045 0.028 Experimental 0.039 0.046 0.01 % degradation 30 0 50 Std boiled 0.049 0.054 0.046 Experimental 0.039 0.046 0.014 % degradation 22 15 70 - Fumonisin was further examined by incubating it as in Table 3, but with an aminoxidase to remove the amine groups. The
lipase 2 again achieved degradation while the oxidase also degraded the toxin. There was no apparent synergy of using both enzymes. This demonstrates that a combination of enzymes, alone, is not effective at improving mycotoxin degradation. -
TABLE 5 Lipase Lipase AE 02 + Blank AEO 2 Oxidase Oxidase Results 0.38 0.45 0.41 0.46 % max abs Ave 20.89 24.91 22.6 23.23 ppm 0.26 0.18 0.2 0.19 % degradation 31.90% 22.10% 26.00% - Enzyme degradation of Zearalenone was examined using a variety of preparations. Of these preparations, some achieved degradation but the composition according to the invention (as defined in Table 1) produced a synergistic effect. Repeats of the experiment followed by analysis by HPLC showed that the formulation was capable of reducing the toxin levels to zero.
-
TABLE 6 Formulation Cellulase defined in From Xylanase Nitrilase Lipase Enzyme Table 1 Table 2 of Table 2 (Control) AE 02 Experimental 0.0010 0.014 0.022 0.024 0.006 Control 0.019 0.015 0.026 0.017 0.012 % reduction 47 7 17 0 12 in apparent toxin concen- tration - Toxin at physiological levels of approx. 200 μg/L was mixed with a constant quantity (50 mg) of binder, agitated for 30 min, centrifuged and the toxin remaining in solution measured using a RIDASCREEN® FAST mycotoxin test kit (available from R-Biopharm GmbH, Darmstadt, Germany). The results are determined by reference to a standard binding curve for the toxin and binder.
- The results are shown in
FIG. 1 , which shows the binding percentage at a typical (physiological) rumen concentration. The binding abilities of various components are demonstrated at a physiological concentration of toxin. It can be seen from the variability in the results that a mixture of binders is preferable to a single entity. (Volclay=Na bentonite; Teragreen=Ca bentonite, FerMOS=polysaccharide binding complex). - In the following experiments (5, 6, 7) active yeast cultures (Saccharomyces Cerevisiae NYCC R404) were charged with the appropriate toxin at 200 μg/L and the disappearance from the supernatant followed by ELISA assays.
-
FIGS. 2 , 3, and 4 illustrate the effects of the microorganism and its endogenous microbial enzymes on the mycotoxins DON, Zearalenone and Fumonisin. In each case, the yeast take up the toxin, rapidly reducing the toxicity of the culture. The toxin is then metabolised and released, in an altered form, where it is able to bind the binding agent, for subsequent degradation. These examples illustrate the synergy of the composition according to the invention. - Yeast (Saccharomyces Cerevisiae NYCC R404) rapidly take up DON from solution, preventing uptake into the animal. The yeast metabolise the DON and release break-down products (metabolites) which are able to bind to two different bentonite binders. Further degradation can then occur on the binders. See
FIG. 2 . - Rapid uptake by yeast (Saccharomyces Cerevisiae NYCC R404) is demonstrated with the toxin Zearalenone. The enzyme modification occurs in the cell and metabolite peak is then produced, as with DON, before it is subsequently degraded. See
FIG. 3 . - Yeast (Saccharomyces Cerevisiae NYCC R404) can remove fumonisin from the gastro-intestinal tract by sequestration, as shown in
FIG. 4 . Again, a peak of metabolites is produced early on before further degradation over time. - Treatment of a small herd receiving contaminated feed. Prior to treatment the 49 head herd exhibited rough hair coat, abortions, scours, erratic appetites, a lower and erratic milk production, feed in manure and stressed demeanour in the animals.
FIG. 5 shows that as the desired formulation (as defined in Table 1) was added, at a rate of 0.5 kilos/1000 kilos of feed for 2 days, and 0.25 kilos 1000 kilos of feed thereafter, milk production increased. Milk production is shown in lbs. - Feed containing corn silage known to be contaminated with Vomitoxin (DON), and determined to be at 16.6 ppm, was fed to a 160 head dairy herd which was used in a one month experiment. Enzymes and binders (as part of the formulation defined in Table 1) were fed at 0.5 kilo per 1000 kilo of total mixed ration. Milk production is shown in
FIG. 6 , adjusted for 150 DIM. - In a group of pigs where reproduction and growth performance was poor and the conception rate was less than 50%, the number born alive was at 5 pigs per litter. Grower finisher days were over 200 days and animals were very variable. A toxin challenge was identified. Feed analysis showed 4.1 and 4.8 ppm of DON. All breeding pigs were immediately placed on feed containing 2.5 kg/tonne of the formulation (as defined in Table 1).
- After 21 days first service, conception was back to normal at over 90% and pigs born alive returned to Greater than 10. Pig feed intake in grower finisher was back to normal. Subsequently, pig variation in grower finisher also returned to normal.
- Boars also benefited. Exposed to DON, their semen volume and sperm concentration decreased by 50% within 7 days. On treatment they returned to normal also in approximately 7 days.
Claims (22)
1. A composition comprising an enzyme, a mycotoxin-binding agent and a saccharomyces yeast capable of taking up a mycotoxin.
2. The composition according to claim 1 , wherein the active agents consist of the enzyme, mycotoxin-binding agent and saccharomyces yeast capable of taking up a mycotoxin.
3. The composition according to claim 1 , wherein the saccharomyces yeast is Saccharomyces cerevisiae.
4. The composition according to claim 1 , wherein the enzyme is an esterase, lipase, protease, oxidase, amino acid oxidase, lactonohydrolase, peroxidase, lactoperoxidase, manganese peroxidase, epoxidase, polysaccharase or dehydrogenase.
5. The composition according to claim 1 , wherein the binder comprises a polysaccharide, such as glucomannan, or a bentonite.
6. The composition according to claim 1 , wherein the microorganism expresses at least one enzyme selected from among an esterase, lipase, protease, oxidase, amino acid oxidase, lactonohydrolase, peroxidase, lactoperoxidase, manganese peroxidase, epoxidase, polysaccharase, and dehydrogenase.
7. The composition according to claim 1 , comprising a further microorganism that expresses at least one enzyme selected from among an esterase, lipase, protease, oxidase, amino acid oxidase, lactonohydrolase, peroxidase, lactoperoxidase, manganese peroxidase, epoxidase, polysaccharase, and dehydrogenase.
8. The composition according to claim 1 for application to a foodstuff.
9. The composition according to claim 1 , wherein the toxin binder is charged.
10. A method of reducing the toxicity of a mycotoxin in a foodstuff, comprising the step of contacting the foodstuff with a composition comprising an enzyme, a mycotoxin-binding agent and a saccharomyces yeast capable of taking up a mycotoxin.
11. The method according to claim 10 , wherein the mycotoxin to be modified is a tricothene.
12. The method according to claim 11 , wherein the tricothene mycotoxin to be modified is Deoxynivalenol.
13. The method according to claim 10 , wherein the mycotoxin to be modified is Zearalenone, Aflatoxin, Fumonisin, Roquefortin, an ochratoxin or an endophyte toxin.
14. The method according to claim 13 , wherein the endophyte is Lolitrem B, sporidesmin or ergovaline.
15. The method according to claim 10 , wherein the foodstuff is contacted with the composition prior to consumption by an animal.
16. The method according to claim 10 , wherein the foodstuff is contacted with the composition simultaneous with consumption by an animal.
17. The method according to claim 10 , wherein the enzyme potentiates the toxin binding to the toxin binder.
18. A foodstuff comprising a composition comprising an enzyme, a mycotoxin-binding agent and a saccharomyces yeast capable of taking up a mycotoxin.
19-21. (canceled)
22. A method for the treatment of a disease caused by mycotoxin in a human or non-human animal, comprising providing a composition to the human or non-human animal for consumption, wherein the composition comprises an enzyme, a mycotoxin-binding agent and a saccharomyces yeast capable of taking up a mycotoxin, and wherein the composition is consumed by the human or non-human animal.
23. The method according to claim 22 , wherein a foodstuff comprising the composition is provided to the human or non-human animal, and wherein the foodstuff is consumed by the human or non-human animal.
24. A method for making a composition, comprising combining an enzyme, a mycotoxin-binding agent and a saccharomyces yeast capable of taking up a mycotoxin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0621792.1 | 2006-11-01 | ||
GBGB0621792.1A GB0621792D0 (en) | 2006-11-01 | 2006-11-01 | Composition |
PCT/GB2007/004191 WO2008053232A2 (en) | 2006-11-01 | 2007-11-01 | Mycotoxin-reducing composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/004191 A-371-Of-International WO2008053232A2 (en) | 2006-11-01 | 2007-11-01 | Mycotoxin-reducing composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/577,567 Division US9901108B2 (en) | 2006-11-01 | 2014-12-19 | Mycotoxin-reducing composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110150853A1 true US20110150853A1 (en) | 2011-06-23 |
Family
ID=37547166
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/447,837 Abandoned US20110150853A1 (en) | 2006-11-01 | 2007-11-01 | Mycotoxin-reducing composition |
US14/577,567 Active 2028-03-01 US9901108B2 (en) | 2006-11-01 | 2014-12-19 | Mycotoxin-reducing composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/577,567 Active 2028-03-01 US9901108B2 (en) | 2006-11-01 | 2014-12-19 | Mycotoxin-reducing composition |
Country Status (13)
Country | Link |
---|---|
US (2) | US20110150853A1 (en) |
EP (1) | EP2094107B1 (en) |
AT (1) | ATE493037T1 (en) |
AU (1) | AU2007315907B2 (en) |
CA (1) | CA2668024C (en) |
DE (1) | DE602007011664D1 (en) |
DK (1) | DK2094107T3 (en) |
ES (1) | ES2357750T3 (en) |
GB (1) | GB0621792D0 (en) |
MX (1) | MX2009004724A (en) |
NZ (1) | NZ576662A (en) |
PL (1) | PL2094107T3 (en) |
WO (1) | WO2008053232A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120219683A1 (en) * | 2009-08-27 | 2012-08-30 | Sud-Chemie Ag | Toxin adsorbent |
WO2014127851A1 (en) * | 2013-02-21 | 2014-08-28 | Direvo Industrial Biotechnology Gmbh | Mycotoxin-binders |
WO2015169847A1 (en) * | 2014-05-06 | 2015-11-12 | Veterinærinstituttet | A method for trichothecene detoxification |
WO2015168751A1 (en) * | 2014-05-09 | 2015-11-12 | Hicare Health Foods Pty Limited | Digestive supplement to mitigate adverse reactions |
WO2016209776A1 (en) * | 2015-06-25 | 2016-12-29 | Lee Tech Llc | A method of and system for producing a high value animal feed additive from a stillage in an alcohol production process |
US9695381B2 (en) | 2012-11-26 | 2017-07-04 | Lee Tech, Llc | Two stage high speed centrifuges in series used to recover oil and protein from a whole stillage in a dry mill process |
CN108893416A (en) * | 2018-06-01 | 2018-11-27 | 河南广安生物科技股份有限公司 | It is a kind of degrade vomitoxin saccharomycete and its application |
US11166478B2 (en) | 2016-06-20 | 2021-11-09 | Lee Tech Llc | Method of making animal feeds from whole stillage |
CN114698767A (en) * | 2022-06-07 | 2022-07-05 | 山东健源生物科技有限公司 | Biological agent for removing mycotoxin in feed as well as preparation method and application of biological agent |
US11427839B2 (en) | 2014-08-29 | 2022-08-30 | Lee Tech Llc | Yeast stage tank incorporated fermentation system and method |
US11623966B2 (en) | 2021-01-22 | 2023-04-11 | Lee Tech Llc | System and method for improving the corn wet mill and dry mill process |
US11680278B2 (en) | 2014-08-29 | 2023-06-20 | Lee Tech Llc | Yeast stage tank incorporated fermentation system and method |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA200901471A1 (en) * | 2008-12-29 | 2010-12-30 | Ооо "Промфермент" | METHODS AND COMPOSITIONS FOR FINE DECOMPOSITION CONTAINING MYCOTOXINS DISTRIBUTED IN NORTHERN AND SOUTHERN LATITUDES |
US8828465B2 (en) * | 2010-05-17 | 2014-09-09 | Kemin Industries, Inc. | Mycotoxin binder |
WO2012037297A1 (en) * | 2010-09-16 | 2012-03-22 | Cubena, Inc. | Mycotoxin binding food and feed additives and processing aids, fungistatic and bacteriostatic plant protecting agents and methods of utilizing the same |
AT513472A1 (en) * | 2012-10-09 | 2014-04-15 | Erber Ag | Enzyme preparation for the transformation of ergopeptins, process therefor and feed and feed or silage additive containing the same |
DK201400146A1 (en) * | 2014-03-16 | 2015-09-28 | Janima Holding Aps | Combination product for bedding in animal husbandry. Product is manufactured as a traditional drying agent for housing and has been added to raw materials in the form of stomach stabilizing starch and fiber, as well as minerals that bind toxins. |
US10674746B2 (en) | 2015-10-27 | 2020-06-09 | Cytozyme Animal Nutrition, Inc. | Animal nutrition compositions and related methods |
CN108473384A (en) | 2015-10-27 | 2018-08-31 | 细胞酶动物营养品公司 | Animal nutrition ingredient and correlation technique |
WO2017083964A1 (en) * | 2015-11-16 | 2017-05-26 | Mycotox Solutions Inc. | Uses of mycotoxin-detoxifying antibodies |
BE1024550B1 (en) * | 2016-12-28 | 2018-04-03 | Impextraco Nv | Composition for use as a toxin eliminator in animals |
CN107012131B (en) * | 2017-01-12 | 2020-11-06 | 中国农业科学院北京畜牧兽医研究所 | Manganese peroxidase, gene thereof and application of manganese peroxidase in mycotoxin detoxification |
EP3430913B1 (en) | 2017-07-20 | 2020-12-02 | Tolsa, S.A. | Composition for binding mycotoxins and its use |
WO2019027988A1 (en) | 2017-07-31 | 2019-02-07 | Poet Research, Inc. | Remediation of toxins in biorefinery process streams |
CN109486776B (en) * | 2018-12-11 | 2021-03-26 | 中国农业科学院北京畜牧兽医研究所 | Manganese peroxidase NfMnP and coding gene and application thereof |
US20210403841A1 (en) | 2020-03-12 | 2021-12-30 | Poet Research, Inc. | Enzymatic degradation of mycotoxins during grain processing |
NZ805733A (en) * | 2021-05-21 | 2024-03-22 | Anpario Plc | Composition for use in the treatment and/or prevention of mycotoxic disease |
CN113693189B (en) * | 2021-09-28 | 2023-11-17 | 中国农业科学院北京畜牧兽医研究所 | Application and method of manganese peroxidase for degrading patulin |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4305876A (en) * | 1976-05-10 | 1981-12-15 | Hoffmann-La Roche, Inc. | Process for the manufacture of tertiary, optically active aliphatic compounds |
US5716820A (en) * | 1994-08-12 | 1998-02-10 | Pioneer Hi-Bred International, Inc. | Fumonisin detoxification enzymes |
US20040208956A1 (en) * | 2001-12-20 | 2004-10-21 | Gerd Schatzmayr | Microorganism for biological detoxification of mycotoxins, namely ochratoxins and/or zearalenons, as well as method and use thereof |
US20050079352A1 (en) * | 2001-05-25 | 2005-04-14 | Joey Glorioso | Expandable microspheres for foam insulation and methods |
WO2005079584A2 (en) * | 2004-02-13 | 2005-09-01 | Roquette Freres | Mean volume of loaves (2 hours 30 min and 3 hours 0 min of rising) |
US20060045934A1 (en) * | 2004-08-25 | 2006-03-02 | Cadbury Adams Usa Llc | Liquid-filled chewing gum composition |
US20060188549A1 (en) * | 2005-01-28 | 2006-08-24 | Block Stephanie S | Animal feed compositions capable of reducing the incidence of fescue toxicosis in mammals |
US20070065413A1 (en) * | 2005-09-22 | 2007-03-22 | Castillo Alejandro R | Livestock anti-acid composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5165946A (en) * | 1990-03-07 | 1992-11-24 | Engelhard Corporation | Animal feed additive and method for inactivating mycotoxins present in animal feeds |
AT504U1 (en) * | 1994-10-19 | 1995-12-27 | Erber Erich Kg | FEED ADDITIVES AND USE OF THE SAME FOR INACTIVATING MYCOTOXINS IN FEEDS OR. IN THE DIGESTIVE WAY OF ANIMALS AND METHOD FOR PRODUCING A FEED |
JP4421777B2 (en) * | 1998-04-17 | 2010-02-24 | オールテック インコーポレイテッド | Composition for demycotoxin of feed |
AU774212B2 (en) * | 1999-05-03 | 2004-06-17 | Alltech, Inc. | Novel compositions and methods for reduction of effects of endophyte-infected forages |
WO2004042060A1 (en) * | 2002-11-08 | 2004-05-21 | University Of Copenhagen | Method of immobilising a protein to a zeolite |
AT501359B1 (en) | 2004-11-16 | 2007-10-15 | Erber Ag | METHOD AND MICROORGANISM FOR THE DETOXIFICATION OF FUMONISINES AND THEIR USE AND FEED ADDITIVE |
-
2006
- 2006-11-01 GB GBGB0621792.1A patent/GB0621792D0/en not_active Ceased
-
2007
- 2007-11-01 EP EP07824430A patent/EP2094107B1/en not_active Revoked
- 2007-11-01 WO PCT/GB2007/004191 patent/WO2008053232A2/en active Application Filing
- 2007-11-01 CA CA2668024A patent/CA2668024C/en not_active Expired - Fee Related
- 2007-11-01 MX MX2009004724A patent/MX2009004724A/en active IP Right Grant
- 2007-11-01 US US12/447,837 patent/US20110150853A1/en not_active Abandoned
- 2007-11-01 ES ES07824430T patent/ES2357750T3/en active Active
- 2007-11-01 AU AU2007315907A patent/AU2007315907B2/en not_active Ceased
- 2007-11-01 PL PL07824430T patent/PL2094107T3/en unknown
- 2007-11-01 AT AT07824430T patent/ATE493037T1/en active
- 2007-11-01 NZ NZ576662A patent/NZ576662A/en not_active IP Right Cessation
- 2007-11-01 DK DK07824430.8T patent/DK2094107T3/en active
- 2007-11-01 DE DE602007011664T patent/DE602007011664D1/en active Active
-
2014
- 2014-12-19 US US14/577,567 patent/US9901108B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4305876A (en) * | 1976-05-10 | 1981-12-15 | Hoffmann-La Roche, Inc. | Process for the manufacture of tertiary, optically active aliphatic compounds |
US5716820A (en) * | 1994-08-12 | 1998-02-10 | Pioneer Hi-Bred International, Inc. | Fumonisin detoxification enzymes |
US20050079352A1 (en) * | 2001-05-25 | 2005-04-14 | Joey Glorioso | Expandable microspheres for foam insulation and methods |
US20040208956A1 (en) * | 2001-12-20 | 2004-10-21 | Gerd Schatzmayr | Microorganism for biological detoxification of mycotoxins, namely ochratoxins and/or zearalenons, as well as method and use thereof |
WO2005079584A2 (en) * | 2004-02-13 | 2005-09-01 | Roquette Freres | Mean volume of loaves (2 hours 30 min and 3 hours 0 min of rising) |
US20070166446A1 (en) * | 2004-02-13 | 2007-07-19 | Roquette Freres | Method for producing a gluten-based baked product |
US20060045934A1 (en) * | 2004-08-25 | 2006-03-02 | Cadbury Adams Usa Llc | Liquid-filled chewing gum composition |
US20060188549A1 (en) * | 2005-01-28 | 2006-08-24 | Block Stephanie S | Animal feed compositions capable of reducing the incidence of fescue toxicosis in mammals |
US20070065413A1 (en) * | 2005-09-22 | 2007-03-22 | Castillo Alejandro R | Livestock anti-acid composition |
Non-Patent Citations (5)
Title |
---|
definition of "express" from http://en.mimi.hu.org/biology/express.htm, 5 pages * |
machine translation of WO/9612414 downloaded from the EPO 2/12/2012. * |
Nurminen et al. Biocehm. J. (1970) 118: 759-763. * |
Shetty et al. Trends in Food Sci. (2006) 12: 48-55. * |
Zhang et al. Journal of AOAC International (2014) 97(3): 889-895. * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120219683A1 (en) * | 2009-08-27 | 2012-08-30 | Sud-Chemie Ag | Toxin adsorbent |
US9695381B2 (en) | 2012-11-26 | 2017-07-04 | Lee Tech, Llc | Two stage high speed centrifuges in series used to recover oil and protein from a whole stillage in a dry mill process |
WO2014127851A1 (en) * | 2013-02-21 | 2014-08-28 | Direvo Industrial Biotechnology Gmbh | Mycotoxin-binders |
US10131866B2 (en) | 2013-02-21 | 2018-11-20 | Direvo Industrial Biotechnology Gmbh | Mycotoxin-binders |
WO2015169847A1 (en) * | 2014-05-06 | 2015-11-12 | Veterinærinstituttet | A method for trichothecene detoxification |
WO2015168751A1 (en) * | 2014-05-09 | 2015-11-12 | Hicare Health Foods Pty Limited | Digestive supplement to mitigate adverse reactions |
US11427839B2 (en) | 2014-08-29 | 2022-08-30 | Lee Tech Llc | Yeast stage tank incorporated fermentation system and method |
US11680278B2 (en) | 2014-08-29 | 2023-06-20 | Lee Tech Llc | Yeast stage tank incorporated fermentation system and method |
US20160374364A1 (en) * | 2015-06-25 | 2016-12-29 | Lee Tech LLC. | Method of and system for producing a high value animal feed additive from a stillage in an alcohol production process |
WO2016209776A1 (en) * | 2015-06-25 | 2016-12-29 | Lee Tech Llc | A method of and system for producing a high value animal feed additive from a stillage in an alcohol production process |
US11166478B2 (en) | 2016-06-20 | 2021-11-09 | Lee Tech Llc | Method of making animal feeds from whole stillage |
CN108893416A (en) * | 2018-06-01 | 2018-11-27 | 河南广安生物科技股份有限公司 | It is a kind of degrade vomitoxin saccharomycete and its application |
US11623966B2 (en) | 2021-01-22 | 2023-04-11 | Lee Tech Llc | System and method for improving the corn wet mill and dry mill process |
CN114698767A (en) * | 2022-06-07 | 2022-07-05 | 山东健源生物科技有限公司 | Biological agent for removing mycotoxin in feed as well as preparation method and application of biological agent |
Also Published As
Publication number | Publication date |
---|---|
AU2007315907A1 (en) | 2008-05-08 |
WO2008053232A2 (en) | 2008-05-08 |
ATE493037T1 (en) | 2011-01-15 |
CA2668024A1 (en) | 2008-05-08 |
US9901108B2 (en) | 2018-02-27 |
EP2094107A2 (en) | 2009-09-02 |
DK2094107T3 (en) | 2011-03-28 |
US20150150285A1 (en) | 2015-06-04 |
AU2007315907B2 (en) | 2012-02-23 |
MX2009004724A (en) | 2009-10-12 |
ES2357750T3 (en) | 2011-04-29 |
PL2094107T3 (en) | 2011-07-29 |
DE602007011664D1 (en) | 2011-02-10 |
GB0621792D0 (en) | 2006-12-13 |
WO2008053232A3 (en) | 2008-08-21 |
EP2094107B1 (en) | 2010-12-29 |
CA2668024C (en) | 2012-06-26 |
NZ576662A (en) | 2012-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9901108B2 (en) | Mycotoxin-reducing composition | |
AU2012200952B2 (en) | Mycotoxin-reducing composition | |
Dierick | Biotechnology aids to improve feed and feed digestion: enzymes and fermentation | |
Francesch et al. | Nutritional factors affecting excreta/litter moisture and quality | |
AU732047B2 (en) | Compositions for removal of mycotoxins from feed | |
Brossard et al. | Dose effect of live yeasts on rumen microbial communities and fermentations during butyric latent acidosis in sheep: new type of interaction | |
McNab et al. | Barley β-glucan: An antinutritional factor in poultry feeding | |
RU2457851C2 (en) | Agent for fermentation improvement in ruminant scars | |
CN109554356B (en) | Mycotoxin biodegradation agent containing glucose oxidase and saccharomyces cerevisiae and application thereof | |
US20180343891A1 (en) | System for and a method of producing enriched and digested probiotic super feed using wet mill and dry mill processes | |
JP2018509173A (en) | Use of trichothecene-converted alcohol dehydrogenase, method for converting trichothecene, and trichothecene-converting additive | |
Sherif | Effect of dietary additives on rabbit performance, carcass traits and some blood constituents under Egyptation summer season | |
Pettersson | Controlling mycotoxins in animal feed H. Pettersson, Swedish University of Agricultural Sciences, Sweden | |
El-Sagheer et al. | Effect of enzymes and probiotic mixture supplementation to the diet of growing female rabbits on performance and carcass criteria | |
AU714602B2 (en) | Animal feed additives | |
Perry | Biotechnology in animal feeds and animal feeding: an overview | |
EP0796048A1 (en) | Micro-organisms, enzymes, and their use | |
Sawsan et al. | Determine the proper level of yeast with different levels of roughages to improve the nutritive value of lamb’s ration | |
CN112293568A (en) | Fermented Chinese herbal medicine and preparation method thereof, and feed mycotoxin mold removal agent and preparation method thereof | |
CN106306407A (en) | Plant-eating animal feed processed by corn cobs and preparation method thereof | |
Edison et al. | Beta-glucanases in animal nutrition | |
Purushothaman et al. | Effect of autoclaving and supplementation of enzyme or yeast culture on feeding value of little millet for broilers | |
Žitñan et al. | The effect of diet composition on the development of rumen digestion in lambs | |
Suttiniyom et al. | Digestibility and protein content improvement of corncob silage using chicken feather partially digested by Bacillus subtilis G8. | |
Kirby et al. | Adaptation to grain feeding |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |